Patent ID: 6680302
Filing Date: 2004-01-20
Classification: A61K,A61P,G01N,Y10T

Abstract:
A method of optimizing therapeutic efficacy for treatment of an immune-mediated gastrointestinal disorder, comprising:(a) administering a drug providing 6-thioguanine to a subject having said immune-mediated gastrointestinal disorder; and (b) determining a level of 6-thioguanine or 6-methyl-mercaptopurine in said subject having said immune-mediated gastrointestinal disorder, wherein a level of 6-thioguanine less than about 230 pmol per 8Ã—108 red blood cells indicates a need to increase the amount of said drug subsequently administered to said subject and wherein a level of 6-thioguanine greater than about 400 pmol per 8Ã—108 red blood cells or a level of 6-methyl-mercaptopurine greater than about 7000 pmol per 8Ã—108 red blood cells indicates a need to decrease the amount of said drug subsequently administered to said subject.